iRhythm Technologies, Inc.
General ticker "IRTC" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $4.7B (TTM average)
iRhythm Technologies, Inc. does not follow the US Stock Market performance with the rate: -22.2%.
Estimated limits based on current volatility of 1.8%: low 106.15$, high 110.14$
Factors to consider:
- Earnings expected soon, date: 2026-10-29 amc
- Total employees count: 2400 (+20.0%) as of 2025
- Top business risk factors: Medicare reimbursement, Market competition, Manufacturing production delays, Third-party risks, Labor/talent shortage/retention
- Current price 18.2% below estimated low
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [132.88$, 263.04$]
- 2026-12-31 to 2027-12-31 estimated range: [108.36$, 223.91$]
Financial Metrics affecting the IRTC estimates:
- Negative: with PPE of -128.9 at the end of fiscal year the price was high
- Negative: Operating cash flow per share per price, % of 1.42 <= 2.37
- Negative: negative Industry operating income (median)
- Negative: 0.47 < Industry inventory ratio change (median), % of 0.70
- Positive: -13.52 < Operating profit margin, % of -7.14
- Negative: 0.41 < Inventory ratio change, % of 0.44
- Negative: negative Industry operating cash flow (median)
- Negative: 12.78 < Shareholder equity ratio, % of 14.97 <= 25.20
- Negative: negative Net income
- Positive: -7.11 < Investing cash flow per share per price, % of -4.87
Short-term IRTC quotes
Long-term IRTC plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $492.68MM | $591.84MM | $747.14MM |
| Operating Expenses | $617.84MM | $707.34MM | $804.54MM |
| Operating Income | $-125.16MM | $-115.50MM | $-57.41MM |
| Non-Operating Income | $2.50MM | $2.78MM | $13.81MM |
| Interest Expense | $3.65MM | $12.82MM | $13.15MM |
| R&D Expense | $60.24MM | $71.46MM | $84.61MM |
| Income(Loss) | $-122.66MM | $-112.72MM | $-43.60MM |
| Taxes | $0.75MM | $0.56MM | $0.95MM |
| Net Income(Loss)* | $-123.41MM | $-113.29MM | $-44.55MM |
| Stockholders Equity | $210.10MM | $90.91MM | $152.75MM |
| Inventory | $13.97MM | $14.04MM | $21.63MM |
| Assets | $433.14MM | $931.45MM | $1,020.04MM |
| Operating Cash Flow | $-50.10MM | $3.39MM | $80.86MM |
| Capital expenditure | $40.42MM | $48.94MM | $46.34MM |
| Investing Cash Flow | $-1.21MM | $-122.98MM | $-277.06MM |
| Financing Cash Flow | $8.82MM | $511.38MM | $12.61MM |
| Earnings Per Share** | $-4.04 | $-3.63 | $-1.39 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.